GLAXOSMITHKLINE (GSK) has signed a strategic partnership with Brisbane-based medical diagnostics firm Ellume, which offers systems based on fluorescent nanoparticles called Quantum Dots that enable "real-time detection of common conditions such as influenza, strep throat and chlamydia".
The pact with GSK Consumer Health is believed to focus on respiratory care, according to a report in The Australian, with founder Sean Parsons saying the deal would "enable the product to scale into a global market" as well as validating the technology.
A key application of Ellume's point-of-care technology is to reduce antimicrobial resistance by accurately diagnosing whether a virus or bacteria is the cause of a respiratory tract infection.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Dec 18
